Alx Oncology Holdings Inc [NASDAQ: ALXO] loss -4.83% or -0.07 points to close at $1.38 with a heavy trading volume of 143565 shares.
It opened the trading session at $1.45, the shares rose to $1.47 and dropped to $1.35, the range by which the price of stock traded the whole day. The daily chart for ALXO points out that the company has recorded 195.38% gains over the past six months.
If we look at the average trading volume of 535.50K shares, ALXO reached to a volume of 143565 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Alx Oncology Holdings Inc [ALXO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALXO shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXO stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Alx Oncology Holdings Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 13, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $2 to $3. The new note on the price target was released on March 06, 2025, representing the official price target for Alx Oncology Holdings Inc stock. Previously, the target price had yet another drop from $12 to $2, while Jefferies kept a Hold rating on ALXO stock. On March 08, 2024, analysts increased their price target for ALXO shares from 10 to 14.
The Price to Book ratio for the last quarter was 1.65, with the Price to Cash per share for the same quarter was set at 1.12.
Trading performance analysis for ALXO stock
Alx Oncology Holdings Inc [ALXO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.12. With this latest performance, ALXO shares dropped by -10.39% in over the last four-week period, additionally plugging by 195.38% over the last 6 months – not to mention a drop of -17.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALXO stock in for the last two-week period is set at 46.72, with the RSI for the last a single of trading hit 0.1631, and the three-weeks RSI is set at 0.1676 for Alx Oncology Holdings Inc [ALXO]. The present Moving Average for the last 50 days of trading for this stock 1.5758, while it was recorded at 1.4260 for the last single week of trading, and 0.9143 for the last 200 days.
Alx Oncology Holdings Inc (ALXO) Capital Structure & Debt Analysis
According to recent financial data for Alx Oncology Holdings Inc. ( ALXO), the Return on Equity (ROE) stands at -118.95%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -80.47%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Alx Oncology Holdings Inc’s Return on Invested Capital (ROIC) is -199.54%, showcasing its effectiveness in deploying capital for earnings.
Alx Oncology Holdings Inc (ALXO) Efficiency & Liquidity Metrics
Based on Alx Oncology Holdings Inc’s (ALXO) latest financial statements, the Debt-to-Equity Ratio is 0.35%, indicating its reliance on debt financing relative to shareholder equity.
Alx Oncology Holdings Inc (ALXO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Alx Oncology Holdings Inc. (ALXO) effectively leverages its workforce, generating an average of -$1350125.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.40% and a Quick Ratio of 2.40%, indicating strong ability to cover short-term liabilities.
Alx Oncology Holdings Inc [ALXO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Alx Oncology Holdings Inc posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALXO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alx Oncology Holdings Inc go to 30.06%.
An analysis of Institutional ownership at Alx Oncology Holdings Inc [ALXO]
There are presently around $66.15%, or 68.00%% of ALXO stock, in the hands of institutional investors. The top three institutional holders of ALXO stocks are: VENBIO PARTNERS LLC with ownership of 9.7 million shares, which is approximately 18.7145%. FMR LLC, holding 7.81 million shares of the stock with an approximate value of $$47.12 million in ALXO stocks shares; and FMR LLC, currently with $$25.45 million in ALXO stock with ownership which is approximately 8.1419%.
